PRA3 is one of several genetically distinct forms of Progressive Retinal Atrophy (PRA) found in dogs. Although different forms of PRA are caused by different genetic mutations, they share a common outcome: the gradual loss of retinal function. The disease primarily affects two types of photoreceptor cells known as rods and cones. Rod cells are responsible for vision in low-light conditions, while cone cells provide vision in bright light and contribute to color perception.
The earliest clinical sign of PRA3 is often night blindness, as rod cells are typically affected before cone cells. Owners may notice that their dog becomes hesitant in dimly lit environments, struggles to navigate in darkness, or appears reluctant to enter unfamiliar areas at night. As retinal degeneration progresses, daytime vision also begins to decline. Affected dogs may start bumping into objects, have difficulty locating toys or food bowls, and show reduced confidence when moving through new surroundings. In advanced stages, complete blindness can occur. Despite significant vision loss, PRA3 is generally not painful, and many dogs adapt remarkably well by relying on their other senses.
The PRA3 DNA Health Test is designed to identify the specific genetic mutation associated with this form of Progressive Retinal Atrophy. Testing is simple, safe, and non-invasive, requiring either a cheek swab or blood sample. The collected sample is analyzed in a specialized laboratory to determine the dog’s genetic status. Since DNA remains unchanged throughout life, testing can be performed at any age, including in puppies before clinical signs develop.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the PRA3 mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is generally not expected to develop the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a significantly increased likelihood of developing PRA3-related Progressive Retinal Atrophy during its lifetime.
Genetic testing for PRA3 provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed mating decisions that help reduce the prevalence of the disease while preserving healthy genetic diversity within the breed population. Avoiding the breeding of two carrier dogs significantly decreases the likelihood of producing affected puppies.
For dog owners, understanding a dog's genetic status allows for proactive eye health monitoring and regular veterinary ophthalmic examinations. Dogs identified as at risk may benefit from periodic retinal evaluations to monitor vision and detect disease progression. While there is currently no cure for PRA3, early diagnosis can help owners prepare for future vision changes and make environmental adjustments that support their dog's safety and quality of life.
The Progressive Retinal Atrophy (PRA3) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine eye health, and helps reduce the impact of this inherited retinal disorder in future generations. Through early detection and informed breeding decisions, breeders and owners can contribute to healthier dogs and improved long-term visual welfare.
